Development of a Target Product Profile for a Proteomic Blood Test to Aid the Diagnosis of Cranial Giant Cell Arteritis - Study protocol

Imagine a medical emergency where time is the only thing standing between a patient and permanent blindness. Giant cell arteritis is exactly that: a condition where the body's immune system mistakenly attacks the arteries in the head, causing them to swell and narrow. If the blood flow to the eyes is blocked, vision can be lost in a matter of days. Because the risk is so high, doctors must act immediately. When a patient shows signs of the disease, they are started on powerful anti-inflammatory steroids right away, often before a diagnosis is confirmed. This is a necessary gamble, but it comes with a heavy cost. Steroids are harsh on the body, and many people who receive them do not actually have the disease. These patients suffer through months of side effects—weight gain, bone thinning, and mood changes—unnecessarily. Currently, doctors rely on a needle biopsy to take a tiny piece of the artery or an ultrasound scan to look for inflammation, but neither method is perfect. The biopsy can miss the disease if the inflammation is patchy, and the ultrasound depends heavily on the skill of the person holding the machine. The result is a diagnostic system that leaves too many people untreated or treats too many people who are healthy.

Researchers in the United Kingdom are working to solve this dilemma by developing a new kind of blood test. Instead of looking at the artery directly, this test would analyze the proteins floating in a patient's blood. Scientists have already found a specific group of eleven proteins that act like a fingerprint for this disease, distinguishing it from other conditions with high accuracy. However, having a promising scientific signal is not the same as having a medical tool that doctors can trust and use. Before a test can be approved for hospitals, the medical community must agree on exactly what it needs to do. It is not enough to know that a test works in a lab; everyone must agree on how accurate it needs to be, how fast it must return results, and how it fits into the daily routine of a specialist clinic. Without these clear rules, a test might be scientifically brilliant but practically useless, or it might be approved for use without being good enough to protect patients.

To bridge this gap, a team of experts has outlined a plan to create a "Target Product Profile." Think of this document as a detailed blueprint or a strict job description for the new blood test. The team is not building the test itself; they are defining the exact specifications it must meet to be considered safe and effective for the National Health Service in the UK. The group includes doctors who treat the disease, scientists who study the proteins, health economists, and crucially, patients and members of the public who have lived with the condition. Their goal is to reach a shared agreement on the minimum standards the test must achieve. For instance, they need to decide how many cases of the disease the test must catch to be considered acceptable, and how many healthy people it must correctly identify as healthy to avoid causing unnecessary harm.

The process they have designed is rigorous and structured, moving through three distinct stages. First, the team will gather to define exactly how the test should be used. They are considering whether it should be a standalone tool that replaces current methods or an assistant that helps doctors make better decisions alongside existing scans and biopsies. They have decided that the test will be used in specialist hospitals for adults suspected of having the disease, regardless of whether they have already started taking steroids. Once the scope is set, the team moves to the drafting phase. Here, they will write down specific numbers and requirements for every aspect of the test, from how the blood sample is handled to how the results are reported. They will use computer models to simulate how different levels of accuracy would affect patient outcomes and costs, ensuring that the targets they set are realistic and beneficial.

The final and most critical stage is building a consensus. The team will use a method called the Delphi process, where experts rate the proposed requirements over several rounds of surveys. In each round, they will vote on whether they agree or disagree with the suggested standards. If a requirement does not receive strong agreement from at least three-quarters of the group, it is not accepted. The team will also open the draft up to the wider public for a month, inviting feedback from anyone interested, including other researchers and patient groups. This ensures that the final blueprint reflects the needs of the entire medical community, not just a small group of specialists. The result will be a published document that tells test developers exactly what they need to build. It will serve as a clear benchmark, signaling to manufacturers and funders what is required to bring this life-saving tool to the bedside.

This work is currently in the planning stage. The paper itself is a protocol, a set of instructions for how the team will reach their agreement. It does not yet contain the final agreed-upon numbers for the test's performance, nor does it claim that the test is ready for use. Instead, it lays out the path forward to ensure that when the test is eventually developed, it will be designed with the right goals in mind. The team is careful to note that the test is intended to aid diagnosis, not to replace the judgment of a doctor. By establishing these clear targets now, they hope to prevent the development of a test that is scientifically interesting but clinically ineffective. The ultimate aim is to reduce the number of people who suffer from the side effects of unnecessary steroid treatment while ensuring that no one with the disease is missed. Through this careful, collaborative process, the researchers hope to turn a promising scientific discovery into a reliable tool that protects patients from both the disease and the risks of over-treatment.